# Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

> **NCT05652868** · PHASE1 · TERMINATED · sponsor: **Mythic Therapeutics** · enrollment: 227 (actual)

## Conditions studied

- NSCLC
- NSCLC Stage IV
- NSCLC Stage IIIB
- Non-Small Cell Lung Cancer
- Advanced Non-Small Cell Squamous Lung Cancer
- Advanced Non-Small Cell Lung Cancer
- Advanced Non-Small Cell Non-Squamous Lung Cancer

## Interventions

- **DRUG:** MYTX-011

## Key facts

- **NCT ID:** NCT05652868
- **Lead sponsor:** Mythic Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-23
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-11-07
- **Target enrollment:** 227 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05652868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05652868, "Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05652868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*